Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard A Franklin

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Molecular Cancer Therapeutics|February 20, 2007
17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell linesClint Mitchell, Margaret A Park, Guo Zhang, et al.
Cancer Biology & Therapy|July 21, 2006
Inhibition of the CaM-kinases augments cell death in response to oxygen radicals and oxygen radical inducing cancer therapies in MCF-7 human breast cancer cellsOswaldo G Rodriguez-Mora, Michelle M Lahair, Mark J Evans, et al.
Sexual Health|October 3, 2018
Baseline characteristics of gay and bisexual men in a HIV pre-exposure prophylaxis demonstration project with equity quotas in Auckland, New ZealandPeter J W Saxton, Sunita Azariah, Richard A Franklin, et al.
Current Pharmaceutical Design|October 22, 2013
Signaling intermediates (MAPK and PI3K) as therapeutic targets in NSCLCLudovica Ciuffreda, Ursula Cesta Incani, Linda S Steelman, et al.
Oncogene|April 30, 2003
Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cellsJohn G Shelton, Linda S Steelman, John T Lee, et al.
Oncotarget|July 7, 2011
Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapyMelissa L Sokolosky, Kristin M Stadelman, William H Chappell, et al.
Aging|April 27, 2022
Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic propertiesJames A McCubrey, Akshaya K Meher, Shaw M Akula, et al.
Cell Cycle (Georgetown, Tex.)|August 27, 2011
Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cellsLinda S Steelman, Patrick Navolanic, William H Chappell, et al.
Methods in Molecular Biology (Clifton, N.J.)|March 6, 2003
Elucidation of signal transduction pathways by transfection of cells with modified oncogenesLinda S Steelman, William L Blalock, Xiao-Yang Wang, et al.
Methods in Molecular Biology (Clifton, N.J.)|March 6, 2003
Fibroblastic, hematopoietic, and hormone responsive epithelial cell lines and culture conditions for elucidation of signal transduction and drug resistance pathways by gene transferLinda S Steelman, William L Blalock, Xiao-Yang Wang, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Molecular Cancer Therapeutics|February 20, 2007
17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell linesClint Mitchell, Margaret A Park, Guo Zhang, et al.
Cancer Biology & Therapy|July 21, 2006
Inhibition of the CaM-kinases augments cell death in response to oxygen radicals and oxygen radical inducing cancer therapies in MCF-7 human breast cancer cellsOswaldo G Rodriguez-Mora, Michelle M Lahair, Mark J Evans, et al.
Sexual Health|October 3, 2018
Baseline characteristics of gay and bisexual men in a HIV pre-exposure prophylaxis demonstration project with equity quotas in Auckland, New ZealandPeter J W Saxton, Sunita Azariah, Richard A Franklin, et al.
Current Pharmaceutical Design|October 22, 2013
Signaling intermediates (MAPK and PI3K) as therapeutic targets in NSCLCLudovica Ciuffreda, Ursula Cesta Incani, Linda S Steelman, et al.
Oncogene|April 30, 2003
Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cellsJohn G Shelton, Linda S Steelman, John T Lee, et al.
Oncotarget|July 7, 2011
Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapyMelissa L Sokolosky, Kristin M Stadelman, William H Chappell, et al.
Aging|April 27, 2022
Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic propertiesJames A McCubrey, Akshaya K Meher, Shaw M Akula, et al.
Cell Cycle (Georgetown, Tex.)|August 27, 2011
Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cellsLinda S Steelman, Patrick Navolanic, William H Chappell, et al.
Methods in Molecular Biology (Clifton, N.J.)|March 6, 2003
Elucidation of signal transduction pathways by transfection of cells with modified oncogenesLinda S Steelman, William L Blalock, Xiao-Yang Wang, et al.
Methods in Molecular Biology (Clifton, N.J.)|March 6, 2003
Fibroblastic, hematopoietic, and hormone responsive epithelial cell lines and culture conditions for elucidation of signal transduction and drug resistance pathways by gene transferLinda S Steelman, William L Blalock, Xiao-Yang Wang, et al.
Pageof 4